{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T17:16:57Z","timestamp":1791911817352,"version":"4.3.4"},"reference-count":36,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2025,7,11]],"date-time":"2025-07-11T00:00:00Z","timestamp":1752192000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,11,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>The ASAS consensus defines \u2018early axial spondyloarthritis (axSpA)\u2019 as symptom duration \u22642\u2009years, a definition derived from expert opinion due to limited evidence. We performed a meta-analysis of randomized placebo-controlled trials (RCTs) of biologic and targeted synthetic DMARDs (bDMARDs\/tsDMARDs) in axSpA to assess the impact of symptom duration on treatment response.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>RCTs in adult axSpA patients comparing b\/tsDMARDs to placebo were identified through systematic literature reviews supporting the ASAS-EULAR management recommendations. Primary outcome was ASAS40 response, with secondary outcomes including disease activity, function and quality of life at each trial\u2019s primary end point. Relative risks (RRs) comparing two groups (shorter vs longer symptom duration) were calculated for efficacy outcomes for each arm and for several thresholds of symptom duration (1\u20135\u2009years). RR ratios (RRRs) were calculated as the ratio of RR of the b\/tsDMARD and placebo arms. Pooled effects were obtained with random-effects meta-analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Eleven bDMARD RCTs, comprising 3272 axSpA patients, were included. No studies involving tsDMARDs met the eligibility criteria. At the 2-year threshold, pooled RR for ASAS40 response was 2.04 (95% CI, 1.48\u20132.84) in early axSpA and 2.28 (95% CI, 1.65\u20133.15) in established disease, yielding an RRR of 0.89 (95% CI, 0.63\u20131.26), with no statistical significance. There were no significant differences between efficacy in shorter and longer symptom duration for other outcomes or across other symptom duration thresholds (3\u20135\u2009years).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Based on a meta-analysis of 11 trials, no significant differences were found in the efficacy of bDMARDs compared with placebo in patients with axSpA with shorter vs longer symptom duration, across thresholds from 2 to 5\u2009years.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/rheumatology\/keaf382","type":"journal-article","created":{"date-parts":[[2025,7,11]],"date-time":"2025-07-11T19:09:43Z","timestamp":1752260983000},"page":"5872-5882","source":"Crossref","is-referenced-by-count":6,"title":["Does symptom duration impact on treatment response in axial spondyloarthritis? A meta-analysis of randomized controlled trials"],"prefix":"10.1093","volume":"64","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9119-5330","authenticated-orcid":false,"given":"Diego","family":"Benavent","sequence":"first","affiliation":[{"name":"Rheumatology Department, Hospital Universitari de Bellvitge , Barcelona,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4527-852X","authenticated-orcid":false,"given":"Victoria","family":"Navarro-Comp\u00e1n","sequence":"additional","affiliation":[{"name":"Rheumatology Department, Hospital Universitario La Paz, IdiPaz , Madrid,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9336-0416","authenticated-orcid":false,"given":"Dafne","family":"Capelusnik","sequence":"additional","affiliation":[{"name":"Care and Public Health Research Institute (CAPHRI), Maastricht University , Maastricht,","place":["The Netherlands"]},{"name":"Department of Rheumatology, Tel Aviv Sourasky Medical Center , Tel Aviv,","place":["Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8899-9087","authenticated-orcid":false,"given":"Sofia","family":"Ramiro","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Leiden University Medical Center , Leiden,","place":["The Netherlands"]},{"name":"Department of Rheumatology, Zuyderland Medical Centre , Heerlen,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,7,11]]},"reference":[{"key":"2025110820491895300_keaf382-B1","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1136\/ard-2022-223296","article-title":"ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update","volume":"82","author":"Ramiro","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"2025110820491895300_keaf382-B2","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1186\/ar4561","article-title":"The window of opportunity: a relevant concept for axial spondyloarthritis","volume":"16","author":"Robinson","year":"2014","journal-title":"Arthritis Res Ther"},{"key":"2025110820491895300_keaf382-B3","doi-asserted-by":"crossref","DOI":"10.1016\/j.semarthrit.2022.152032","article-title":"How is early spondyloarthritis defined in the literature? Results from a systematic review","volume":"55","author":"Benavent","year":"2022","journal-title":"Semin Arthritis Rheum"},{"key":"2025110820491895300_keaf382-B4","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1136\/ard-2023-224232","article-title":"ASAS consensus definition of early axial spondyloarthritis","volume":"83","author":"Navarro-Comp\u00e1n","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"2025110820491895300_keaf382-B5","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1093\/rheumatology\/keac532","article-title":"Treating spondyloarthritis early: does it matter? Results from a systematic literature review","volume":"62","author":"Capelusnik","year":"2023","journal-title":"Rheumatology (Oxford)"},{"key":"2025110820491895300_keaf382-B6","doi-asserted-by":"crossref","first-page":"105603","DOI":"10.1016\/j.jbspin.2023.105603","article-title":"Looking through the window of opportunity in axial spondyloarthritis?","volume":"90","author":"Benavent","year":"2023","journal-title":"Joint Bone Spine"},{"key":"2025110820491895300_keaf382-B7","doi-asserted-by":"crossref","first-page":"1759720","DOI":"10.1177\/1759720X221081649","article-title":"Delayed treatment with a tumor necrosis factor alpha blocker associated with worse outcomes in patients with spondyloarthritis: data from the Czech National Registry ATTRA","volume":"14","author":"Milota","year":"2022","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"2025110820491895300_keaf382-B8","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1007\/s10067-017-3965-2","article-title":"Health-related quality of life outcomes in patients with rheumatoid arthritis and ankylosing spondylitis after tapering biologic treatment","volume":"37","author":"Chen","year":"2018","journal-title":"Clin Rheumatol"},{"key":"2025110820491895300_keaf382-B9","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1002\/art.40866","article-title":"A fifty-two\u2013week, randomized, placebo-controlled trial of certolizumab pegol in nonradiographic axial spondyloarthritis","volume":"71","author":"Deodhar","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"2025110820491895300_keaf382-B10","doi-asserted-by":"crossref","first-page":"n160","DOI":"10.1136\/bmj.n160","article-title":"PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"2025110820491895300_keaf382-B11","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1136\/ard-2022-223298","article-title":"Efficacy and safety of biological DMARDs: a systematic literature review informing the 2022 update of the ASAS-EULAR recommendations for the management of axial spondyloarthritis","volume":"82","author":"Webers","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"2025110820491895300_keaf382-B12","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1093\/rheumatology\/kes026","article-title":"Update of the literature review on treatment with biologics as a basis for the first update of the ASAS\/EULAR management recommendations of ankylosing spondylitis","volume":"51","author":"Baraliakos","year":"2012","journal-title":"Rheumatology (Oxford)"},{"key":"2025110820491895300_keaf382-B13","doi-asserted-by":"crossref","first-page":"e000396","DOI":"10.1136\/rmdopen-2016-000396","article-title":"Efficacy and safety of biological and targeted-synthetic DMARDs: a systematic literature review informing the 2016 update of the ASAS\/EULAR recommendations for the management of axial spondyloarthritis","volume":"3","author":"Sepriano","year":"2017","journal-title":"RMD Open"},{"key":"2025110820491895300_keaf382-B14","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"2025110820491895300_keaf382-B15"},{"key":"2025110820491895300_keaf382-B16"},{"key":"2025110820491895300_keaf382-B17"},{"key":"2025110820491895300_keaf382-B18","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1093\/rheumatology\/keu132","article-title":"Safety and efficacy of golimumab in Chinese patients with active ankylosing spondylitis: 1-year results of a multicentre, randomized, double-blind, placebo-controlled phase III trial","volume":"53","author":"Bao","year":"2014","journal-title":"Rheumatology (Oxford)"},{"key":"2025110820491895300_keaf382-B19","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1136\/annrheumdis-2012-201766","article-title":"Extended report: efficacy and safety of adalimumab in patients with non-radiographic axial spondyloarthritis: results of a randomised placebo-controlled trial (ABILITY-1)","volume":"72","author":"Sieper","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"2025110820491895300_keaf382-B20","doi-asserted-by":"crossref","first-page":"3402","DOI":"10.1002\/art.23969","article-title":"Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial","volume":"58","author":"Inman","year":"2008","journal-title":"Arthritis Rheum"},{"key":"2025110820491895300_keaf382-B21","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1002\/art.38721","article-title":"Symptomatic efficacy of etanercept and its effects on objective signs of inflammation in early nonradiographic axial spondyloarthritis: a multicenter, randomized, double-blind, placebo-controlled trial","volume":"66","author":"Dougados","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"2025110820491895300_keaf382-B22","doi-asserted-by":"crossref","first-page":"2702","DOI":"10.1002\/art.39257","article-title":"A randomized, double-blind, placebo-controlled, sixteen-week study of subcutaneous golimumab in patients with active nonradiographic axial spondyloarthritis","volume":"67","author":"Sieper","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"2025110820491895300_keaf382-B23","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0140-6736(19)32971-X","article-title":"Ixekizumab for patients with non-radiographic axial spondyloarthritis (COAST-X): a randomised, placebo-controlled trial","volume":"395","author":"Deodhar","year":"2020","journal-title":"Lancet"},{"key":"2025110820491895300_keaf382-B24","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1136\/annrheumdis-2013-204231","article-title":"Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo-controlled Phase 3 study","volume":"73","author":"Landew\u00e9","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"2025110820491895300_keaf382-B25","doi-asserted-by":"crossref","first-page":"341","DOI":"10.3899\/jrheum.170487","article-title":"Safety and efficacy of golimumab administered intravenously in adults with ankylosing spondylitis: results through week 28 of the GO-ALIVE study","volume":"45","author":"Deodhar","year":"2018","journal-title":"J Rheumatol"},{"key":"2025110820491895300_keaf382-B26","doi-asserted-by":"crossref","first-page":"1759720X211051471","DOI":"10.1177\/1759720X211051471","article-title":"Rapid improvement in spinal pain in patients with axial spondyloarthritis treated with secukinumab: primary results from a randomized controlled phase-IIIb trial","volume":"13","author":"Poddubnyy","year":"2021","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"2025110820491895300_keaf382-B27","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1002\/art.41477","article-title":"Improvement of signs and symptoms of nonradiographic axial spondyloarthritis in patients treated with secukinumab: primary results of a randomized, placebo-controlled phase III study","volume":"73","author":"Deodhar","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"2025110820491895300_keaf382-B28","doi-asserted-by":"publisher","first-page":"iv61","DOI":"10.1136\/ard.2005.042432","article-title":"How early should ankylosing spondylitis be treated with tumour necrosis factor blockers?","volume":"64","author":"Sieper","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"2025110820491895300_keaf382-B29","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1136\/annrheumdis-2012-203201","article-title":"Efficacy and safety of infliximab plus naproxen versus naproxen alone in patients with early, active axial spondyloarthritis: results from the double-blind, placebo-controlled INFAST study, Part 1","volume":"73","author":"Sieper","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"2025110820491895300_keaf382-B30","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1136\/ard.2007.073098","article-title":"MRI in predicting a major clinical response to anti-tumour necrosis factor treatment in ankylosing spondylitis","volume":"67","author":"Rudwaleit","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"2025110820491895300_keaf382-B31","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.3899\/jrheum.140056","article-title":"Consistently good clinical response in patients with early axial spondyloarthritis after 3 years of continuous treatment with etanercept: longterm data of the ESTHER trial","volume":"41","author":"Song","year":"2014","journal-title":"J Rheumatol"},{"key":"2025110820491895300_keaf382-B32","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2023-003455","article-title":"Early axial spondyloarthritis according to the ASAS consensus definition: characterisation of patients and effectiveness of a first TNF inhibitor in a large observational registry","volume":"9","author":"Ciurea","year":"2023","journal-title":"RMD Open"},{"key":"2025110820491895300_keaf382-B33","doi-asserted-by":"crossref","first-page":"e000870","DOI":"10.1136\/rmdopen-2018-000870","article-title":"Window of opportunity in rheumatoid arthritis\u2014definitions and supporting evidence: from old to new perspectives","volume":"5","author":"Burgers","year":"2019","journal-title":"RMD Open"},{"key":"2025110820491895300_keaf382-B34","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1136\/annrheumdis-2013-204055","article-title":"Evolution of radiographic damage in ankylosing spondylitis: a 12 year prospective follow-up of the OASIS study","volume":"74","author":"Ramiro","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"2025110820491895300_keaf382-B35","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1136\/ard-2023-225184","article-title":"Sacroiliac radiographic progression over 10 years in axSpA: data from the DESIR inception cohort","volume":"83","author":"Molto","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"2025110820491895300_keaf382-B36","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1002\/acr.23796","article-title":"Spinal radiographic progression in early axial spondyloarthritis: five-year results from the DESIR cohort","volume":"71","author":"Ramiro","year":"2019","journal-title":"Arthritis Care Res (Hoboken)"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/keaf382\/63730410\/keaf382.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/64\/11\/5872\/63730410\/keaf382.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/64\/11\/5872\/63730410\/keaf382.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,9]],"date-time":"2025-11-09T01:49:25Z","timestamp":1762652965000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/64\/11\/5872\/8196877"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,11]]},"references-count":36,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025,7,11]]},"published-print":{"date-parts":[[2025,11,1]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keaf382","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,11]]},"published":{"date-parts":[[2025,7,11]]}}}